Rhythm Launches IMCIVREE in Japan, First Approved Therapy for Acquired Hypothalamic Obesity
RYTM sits 17% above its 52-week low of $74.5.
Summary
Rhythm Pharmaceuticals has commercially launched IMCIVREE (setmelanotide) in Japan for acquired hypothalamic obesity, following its inclusion on Japan's National Health Insurance drug price list. This is the first approved therapy for this indication in Japan, where the company estimates 5,000 to 8,000 patients. The launch follows the August MHLW approval and builds on the drug's U.S. and European commercial footprint. The NHI listing is a critical step for reimbursement and market access in Japan, a key commercial market for the company's global expansion.
At the time of this announcement, RYTM was trading at $87.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.